A gene therapy let deaf children hear for the first time. The treatment delivers a working copy of a faulty gene to the inner ear. Early trials reported meaningful, sometimes dramatic, hearing gains.
Fix the gene
The cause is genetic. A single faulty gene disrupts hearing. Therapy supplies a working copy.
Inner-ear delivery
Targeting is precise. The therapy reaches cells of the cochlea. Delivery is delicate.
Hearing gains
Results moved families. Some children heard speech for the first time. Effects were striking.
Specific form
Scope is defined. It treats a particular inherited deafness. Others need different fixes.
Durability
Questions remain. How long benefits last is unknown. Follow-up continues.
Expanding targets
Ambition grows. Other genetic deafness forms are studied. The field advances.
The bottom line
A gene therapy delivered a working gene to the inner ear and restored hearing in children with an inherited deafness. Early gains were dramatic. Durability and broader forms are the next questions.
